USPTO's Lax Policy Leads to Humira Formulation Thicket.

IF 1.6 4区哲学 Q2 ETHICS

Journal of Law Medicine & Ethics Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI:10.1017/jme.2024.132

Bernard Chao

引用次数: 0

Abstract

Biosimilar drugs enter the United States market well after they enter the European market. That is likely because pharmaceutical companies have many more patents in the United States than in Europe. But why is patent coverage of biological drugs so much more extensive in United States? This case study seeks to answer this question for drug formulation patents.

查看原文本刊更多论文

美国专利商标局的宽松政策导致 Humira 制剂陷入困境。

生物仿制药进入美国市场的时间远远晚于进入欧洲市场的时间。这可能是因为制药公司在美国拥有的专利比欧洲多得多。但为什么美国的生物药品专利覆盖面如此之广？本案例研究试图从药物制剂专利方面回答这个问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Law Medicine & Ethics 医学-医学：法

CiteScore

2.90

自引率

4.80%

发文量

审稿时长

6-12 weeks

期刊介绍： Material published in The Journal of Law, Medicine & Ethics (JLME) contributes to the educational mission of The American Society of Law, Medicine & Ethics, covering public health, health disparities, patient safety and quality of care, and biomedical science and research. It provides articles on such timely topics as health care quality and access, managed care, pain relief, genetics, child/maternal health, reproductive health, informed consent, assisted dying, ethics committees, HIV/AIDS, and public health. Symposium issues review significant policy developments, health law court decisions, and books.